| Autor: |
Han-En Wang, Chun-Ting Chen, Hsin-Hung Huang |
| Jazyk: |
angličtina |
| Rok vydání: |
2014 |
| Předmět: |
|
| Zdroj: |
Journal of Medical Sciences, Vol 34, Iss 3, Pp 126-128 (2014) |
| Druh dokumentu: |
article |
| ISSN: |
1011-4564 |
| DOI: |
10.4103/1011-4564.134392 |
| Popis: |
Sorafenib was approved in 2005 for the treatment of metastatic renal cell carcinoma and advanced hepatocellular carcinoma (HCC). Acute pancreatitis is a side-effect of sorafenib usage. We present a patient with advanced HCC who presented with acute Grade D pancreatitis caused by sorafenib administration. Following the discontinuation of sorafenib, fasting, and fluid replacement, the patient′s clinical manifestation of Grade D pancreatitis subsided in a short time. One month after discharge, she resumed sorafenib treatment (200 mg/day) due to disease progression. Based on this experience, resumption of sorafenib treatment appears to be safe. |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
